At the news
? NEUTRALIMPACT 2/10 6-K filed Jun 29, 2026 at 16:05 ET
Ascendis Pharma reported the closing of a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 ordinary shares at an average cash consideration of approximately $121.57 per share. The company's share capital increased to DKK 66,189,926, and the articles of association were amended accordingly. This is a routine administrative filing with no material impact on the company's operations or financial outlook.
- 177,267 ordinary shares issued upon exercise of warrants at an average cash consideration of approximately $121.57 per share.
- Share capital increased to DKK 66,189,926.
- Articles of association amended to reflect the capital increase.
- Exercise window closed on June 29, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access